For the past few years, Section 174 fundamentally changed how companies experienced the cost of R&D.
What used to be an immediate deduction became a forced capitalization regime — and for many tech companies, that created real cash-flow pain.
But starting in tax year 2025, an important shift changes the landscape again.
Domestic R&D is once again immediately deductible.
Foreign R&D is not.
That single distinction now drives one of the most important — and underappreciated — tax strategy decisions for software and technology companies.
What Changed in 2025 (and What Didn’t)
Beginning in tax year 2025:
- U.S.-based R&D expenses under Section 174 are fully deductible in the year incurred
- Foreign-based R&D expenses remain subject to 15-year amortization
This effectively restores the pre-TCJA treatment for domestic research — while leaving foreign research under a much harsher regime.
The result is a clear structural preference for U.S. innovation baked directly into the tax code.
Why This Is a Bigger Deal Than It Sounds
Immediate deductibility isn’t just an accounting technicality.
It affects:
- taxable income,
- cash flow,
- deferred tax balances,
- and how expensive innovation feels in real time.
For companies doing meaningful R&D, the difference between:
- deducting costs now, versus
- spreading them over 15 years,
can materially change hiring decisions, team location, and long-term planning.
Domestic R&D Now Has a Double Advantage
With the 2025 change, domestic R&D benefits from two powerful levers:
- Immediate deductibility under Section 174, and
- Eligibility for the R&D tax credit under Section 41.
That combination means U.S. R&D can:
- reduce taxable income right away,
- generate current-year or future tax credits,
- and create long-lived tax attributes through carryforwards.
Foreign R&D gets none of that symmetry.
Even if the headline labor cost is lower, the tax friction is dramatically higher.
The Credit Stack Matters More Now
The R&D credit still:
- applies only to qualified U.S. research,
- can offset income tax or payroll tax,
- and carries forward for 20 years federally.
When paired with immediate deductibility, the effective cost of domestic R&D drops significantly.
This is why many companies are discovering that:
“More expensive” domestic engineers can be cheaper after tax than offshore teams.
The math often surprises people — but it’s very real.
Why This Matters for Scaling and M&A
For companies thinking beyond the current year, this shift is even more important.
Domestic R&D:
- creates cleaner tax attributes,
- avoids long amortization tails,
- improves earnings quality,
- and simplifies diligence for investors and acquirers.
Foreign R&D, by contrast:
- builds up long-dated deferred tax assets,
- suppresses near-term earnings,
- and often raises questions during deal review.
In acquisition contexts, buyers care deeply about:
- how credits were generated,
- whether deductions were properly taken,
- and whether tax attributes are usable.
Domestic R&D checks those boxes far more cleanly.
This Is No Longer Just a Tax Rule — It’s a Strategy Signal
Congress didn’t make this change accidentally.
The 2025 shift sends a clear message:
U.S.-based innovation is being explicitly favored.
For tech companies, this turns Section 174 into a strategic lens — not just a compliance issue.
Where you place R&D now affects:
- near-term cash flow,
- long-term tax efficiency,
- and enterprise value.
The Takeaway
Starting in 2025, domestic R&D is uniquely advantaged:
- fully deductible,
- credit-eligible,
- and valuation-friendly.
Foreign R&D remains more expensive from a tax perspective — even if it looks cheaper on paper.
Companies that align their R&D footprint with this reality aren’t gaming the system.
They’re responding rationally to the incentives written into the code.
